Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 14/20 | 0.38 |
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181911 | 0.89 | EIF2AK3 (0.37) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20182196 | 0.89 | EIF2AK3 (0.37) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20182274 | 0.82 | EIF2AK3 (0.40) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20182190 | 0.80 | CFTR (0.35) | — | |
| SCHEMBL20182264 | 0.79 | SRC (0.35) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20182213 | 0.76 | SRC (0.42) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20162959 | 0.73 | SRC (0.41) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20182227 | 0.72 | EGFR (0.36) | EIF2AK3SRCLCKTEK | |
| SCHEMBL20182281 | 0.72 | FLT3 (0.39) | EIF2AK3SRC | |
| SCHEMBL20181916 | 0.72 | CFTR (0.39) | EIF2AK3SRCLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | EIF2AK3 2813/4885SRC 3551/4885LCK 1198/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | EIF2AK3 2867/4885SRC 3742/4885LCK 1455/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | EIF2AK3 2867/4885SRC 3742/4885LCK 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.